<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Seasonal influenza in adults: Role of antiviral prophylaxis for prevention
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Seasonal influenza in adults: Role of antiviral prophylaxis for prevention
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Seasonal influenza in adults: Role of antiviral prophylaxis for prevention
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kimon C Zachary, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin S Hirsch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 12, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seasonal influenza is an acute respiratory illness caused by influenza A or B viruses. Vaccination is the most important intervention for prevention of influenza. Antiviral drugs may be useful adjunctive tools for patients at high risk of influenza complications for whom influenza vaccine is contraindicated, unavailable, or expected to have low effectiveness (eg, due to immunosuppression or mismatch between vaccine antigens and circulating virus strains); however, they should not be used as a substitute for vaccination.
        </p>
        <p>
         Our recommendations are generally in keeping with those of the United States Centers for Disease Control and Prevention and the Infectious Diseases Society of America [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         The role of antiviral drugs for prevention of seasonal influenza will be reviewed here. Issues related to treatment of seasonal influenza are discussed separately, as are the pharmacologic characteristics of the antiviral drugs and issues related to antiviral drug resistance. (See
         <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">
          "Seasonal influenza in nonpregnant adults: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7008.html" rel="external">
          "Antiviral drugs for influenza: Pharmacology and resistance"
         </a>
         .)
        </p>
        <p>
         Issues related to antiviral drugs for prevention of seasonal influenza in hematopoietic cell transplant and lung transplant recipients are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16533.html" rel="external">
          "Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Chemoprophylaxis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13952.html" rel="external">
          "Viral infections following lung transplantation", section on 'Antiviral prophylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3810262443">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Definitions
         </span>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          High-risk individuals
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals at high risk for influenza complications are summarized in the table  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="headingAnchor" id="H837889">
         <span class="h3">
          Close contact
         </span>
         <span class="headingEndMark">
          —
         </span>
         A close contact is an individual who has cared for or lived with a person who has confirmed, probable, or suspected influenza infection or who has been in a setting where there was a high likelihood of contact with respiratory droplets and/or body fluids of such a person; this includes speaking face-to-face with a person with suspected or confirmed influenza infection [
         <a href="#rid3">
          3
         </a>
         ]. Face masks likely mitigate this risk, though data are limited [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3115081475">
         <span class="h2">
          Antiviral agents
         </span>
        </p>
        <p class="headingAnchor" id="H283320962">
         <span class="h3">
          Drug classes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Classes of antiviral drugs for prevention of influenza include  (
         <a class="graphic graphic_table graphicRef50350" href="/z/d/graphic/50350.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuraminidase inhibitors
         </strong>
         − Neuraminidase inhibitors approved by the US Food and Drug Administration (FDA) for pre-exposure and postexposure prevention of influenza include
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         and
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          Peramivir
         </a>
         , an intravenous neuraminidase inhibitor, has been approved by the FDA for treatment of influenza but not for prevention of influenza.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Laninamivir, a long-acting inhaled neuraminidase inhibitor not available in the United States, has been reported to be effective for preventing infection among household contacts of patients with influenza [
         <a href="#rid5">
          5
         </a>
         ]; it is approved for use in Japan but remains investigational elsewhere.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endonuclease inhibitor
         </strong>
         −
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          Baloxavir
         </a>
         is approved by the FDA for postexposure prophylaxis among nonpregnant adults, but not for pre-exposure prevention of influenza.
        </p>
        <p>
        </p>
        <p>
         Due to emergence of high rates of adamantane resistance among influenza A viruses, the United States Centers for Disease Control and Prevention recommends that adamantanes (
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          amantadine
         </a>
         and
         <a class="drug drug_general" data-topicid="9866" href="/z/d/drug information/9866.html" rel="external">
          rimantadine
         </a>
         )
         <strong>
          not
         </strong>
         be used for the treatment of influenza in the United States [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1596669421">
         <span class="h3">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          Oseltamivir
         </a>
         can cause nausea and vomiting (15 percent of patients), but these effects are usually mild and do not generally result in discontinuation of therapy.
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          Zanamivir
         </a>
         (inhaled) can cause bronchospasm in patients with asthma and other chronic respiratory disorders; therefore, this agent is contraindicated in these patient groups.
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          Baloxavir
         </a>
         is generally well tolerated.
        </p>
        <p>
         Additional issues related to adverse effects of antiviral drugs are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/7008.html" rel="external">
          "Antiviral drugs for influenza: Pharmacology and resistance"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2087252921">
         <span class="h1">
          COMMUNITY SETTINGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         General principles related to use of antiviral drugs for prevention of seasonal influenza are discussed below.
        </p>
        <p>
         Issues related to antiviral drugs for prevention of seasonal influenza in hematopoietic cell transplant and lung transplant recipients are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16533.html" rel="external">
          "Prevention of viral infections in hematopoietic cell transplant recipients", section on 'Chemoprophylaxis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13952.html" rel="external">
          "Viral infections following lung transplantation", section on 'Antiviral prophylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1953586409">
         <span class="h2">
          Pre-exposure antiviral prophylaxis
         </span>
        </p>
        <p class="headingAnchor" id="H3345410867">
         <span class="h3">
          Clinical approach
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recipients, timing, and duration
         </strong>
         − In community settings, there is no role for routine use of antiviral drugs for prevention of influenza. Such use may be reasonable in the following limited situations, during community influenza transmission [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Category I
         </strong>
         − Individuals at high risk of influenza complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ) for whom influenza vaccination is contraindicated, unavailable, or expected to have low effectiveness (eg, due to immunosuppression or mismatch between vaccine antigens and circulating virus strains). United States influenza surveillance data are available at the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fflu%2Fweekly%2Findex.htm%3Fweb%3D1%26wdLOR%3DcB3CCE869-5532-4A65-AF12-06BD9073457C&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLOtzxb%2BvTZhOOrHrvoZzklF9wKFoFcJP%2BVYs1saQ3FFichIsFv%2BKj0VWK16hCvObui5o4asN6xGX64EvoCgBxodbqwo4c6S3J91dIrFieC5FJChdp%2FWF3yrzgAdtO8%2FJNQ%3D%3D&amp;TOPIC_ID=7017" target="_blank">
          United States Centers for Disease Control and Prevention website
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Pre-exposure prophylaxis should be initiated as soon as influenza activity is detected in the community and continued for the duration of community influenza activity [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Category II
         </strong>
         − Individuals at high risk of influenza complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ) for whom influenza vaccination is expected to be effective but has not yet been administered.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Vaccination should be administered promptly; short-term pre-exposure prophylaxis may be administered for two weeks until the immune response to the vaccine develops.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Category III
         </strong>
         – Individuals for whom influenza vaccination is contraindicated, unavailable, or expected to have low effectiveness, who are in close contact with individuals in the above categories who are unable to take chemoprophylaxis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Pre-exposure prophylaxis should be initiated for the duration of close contact, during community influenza activity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A reasonable alternative to pre-exposure prophylaxis is early initiation of therapy for patients who develop symptomatic illness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiviral selection
         </strong>
         – Antiviral agents for pre-exposure prophylaxis include oral
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         or inhaled
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         ; dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef50350" href="/z/d/graphic/50350.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If oseltamivir-resistant influenza is suspected,
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         should be used. (See
         <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">
          "Seasonal influenza in nonpregnant adults: Treatment", section on 'Antiviral resistance'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7008.html" rel="external">
          "Antiviral drugs for influenza: Pharmacology and resistance"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          If symptomatic illness develops
         </strong>
         − For individuals receiving pre-exposure prophylaxis who develop signs or symptoms of influenza, diagnostic testing should be pursued, pre-exposure prophylaxis should be discontinued, and antiviral treatment should be administered (preferably with an antiviral drug with a different resistance profile if not contraindicated). (See
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">
          "Seasonal influenza in nonpregnant adults: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15870.html" rel="external">
          "Seasonal influenza and pregnancy", section on 'Antiviral treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients receiving pre-exposure prophylaxis with
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         may be treated with
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         or
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         . Patients receiving pre-exposure prophylaxis with zanamivir may be treated with baloxavir; case reports have described zanamivir cross-resistance to oseltamivir and
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          peramivir
         </a>
         [
         <a href="#rid6">
          6-8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H541103742">
         <span class="h3">
          Supporting evidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Randomized trials evaluating pre-exposure prophylaxis include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A trial including more than 1550 unvaccinated healthy adults in which patients were randomly assigned to administration of
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         or placebo for six weeks during a peak period of local influenza virus activity; development of symptomatic, laboratory-confirmed influenza occurred less frequently among those who received oseltamivir (13/1040 versus 25/519; protective efficacy 74 percent [95% CI 53-88 percent]) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A trial including more than 3300 adults and adolescents at high risk of influenza complications in which patients were randomly assigned to inhaled
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         or placebo for 28 days; development of symptomatic, laboratory-confirmed influenza occurred less frequently among those who received zanamivir (4/1678 versus 23/1685; relative risk 0.17 [95% CI 0.07-0.44]) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H155239410">
         <span class="h2">
          Postexposure antiviral prophylaxis
         </span>
        </p>
        <p class="headingAnchor" id="H2931606093">
         <span class="h3">
          Clinical approach
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recipients
         </strong>
         − In community settings, there is no role for routine use of antiviral drugs for prevention of influenza. Such use may be reasonable in the following limited situations (during community influenza transmission, within 48 hours of exposure, and in the absence of symptoms) [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Category I
         </strong>
         – Individuals at high risk of influenza complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ) for whom influenza vaccination is contraindicated, unavailable, or expected to have low effectiveness (eg, due to immunosuppression or mismatch between vaccine antigens and circulating virus strains), after household influenza exposure.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Category II
         </strong>
         – Unvaccinated individuals who are household contacts of a person at high risk of influenza complications, after influenza exposure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A reasonable alternative to postexposure prophylaxis is early initiation of therapy for patients who develop symptomatic illness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing and duration
         </strong>
         – Postexposure prophylaxis should be initiated as soon as possible, within 48 hours after exposure. There is no role for initiation of postexposure prophylaxis if &gt;48 hours have elapsed since exposure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Outside the context of an outbreak, the duration of postexposure prophylaxis is seven days [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to administration of postexposure prophylaxis, unvaccinated individuals should be vaccinated promptly.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiviral selection
         </strong>
         – Antiviral agents for postexposure prophylaxis include
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         ,
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         , and
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         ; dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef50350" href="/z/d/graphic/50350.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If oseltamivir-resistant influenza is suspected,
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         or
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         should be used. (See
         <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">
          "Seasonal influenza in nonpregnant adults: Treatment", section on 'Antiviral resistance'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7008.html" rel="external">
          "Antiviral drugs for influenza: Pharmacology and resistance"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Caution regarding widespread use of
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         for prophylaxis is warranted given its vulnerability to emergence of resistance. In addition, baloxavir is not recommended for pregnant or postpartum patients given lack of safety and efficacy data [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          If symptomatic illness develops
         </strong>
         – For individuals receiving postexposure prophylaxis who develop signs or symptoms of influenza, diagnostic testing should be pursued, postexposure prophylaxis should be discontinued, and antiviral treatment should be administered (preferably with an antiviral drug with a different resistance profile if not contraindicated). (See
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">
          "Seasonal influenza in nonpregnant adults: Treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15870.html" rel="external">
          "Seasonal influenza and pregnancy", section on 'Antiviral treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients receiving prophylaxis with
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         , treatment options include
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         or
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         . For patients receiving prophylaxis with zanamivir, treatment with baloxavir is preferred, given possible cross-resistance to other neuraminidase inhibitors. For patients receiving prophylaxis with baloxavir, treatment options include oseltamivir or zanamivir.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3670507378">
         <span class="h3">
          Supporting evidence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies evaluating postexposure prophylaxis include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A systematic review evaluating the efficacy of postexposure prophylaxis against symptomatic laboratory-confirmed symptomatic influenza including two trials of
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         and three trials of
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         ; the pooled efficacy of these drugs was 81 percent (95% CI 55-92 percent) and 79 percent (95% CI 67-87 percent), respectively [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized trial including 749 household contacts of 545 index patients with influenza in Japan [
         <a href="#rid13">
          13
         </a>
         ]; the risk of influenza was lower among household contacts who received postexposure prophylaxis with
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         than among those who received placebo (1.9 versus 13.6 percent; adjusted risk ratio 0.14, 95% CI 0.06-0.30).
        </p>
        <p>
        </p>
        <p>
         No data are available on the efficacy of postexposure prophylaxis for prevention of serious complications of influenza.
        </p>
        <p class="headingAnchor" id="H1063066434">
         <span class="h1">
          INSTITUTIONAL OUTBREAK CONTROL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Influenza vaccine should be administered to all adults in institutional settings each season. Antiviral drugs may be a useful adjunctive tool but should not be used as a substitute for vaccination.
        </p>
        <p class="headingAnchor" id="H25994336">
         <span class="h2">
          Active surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following circumstances warrant implementation of active surveillance [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a long-term care facility − Identification of one laboratory-confirmed case of influenza
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a hospital − Identification of one health care-associated laboratory-confirmed case of influenza
        </p>
        <p>
        </p>
        <p>
         Active surveillance should consist of daily assessment for signs and symptoms of influenza among all patients in the facility; influenza testing should be pursued for those with new respiratory symptoms (increased work of breathing, coughing, or sneezing), with or without fever; in the absence of respiratory symptoms, influenza testing also should be pursued for abnormal temperature (elevation or reduction) or behavioral changes.
        </p>
        <p>
         Use of molecular diagnostic assays is preferred for optimal sensitivity; tools for diagnosis of influenza are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         Empiric antiviral treatment should be initiated for newly symptomatic individuals as soon as possible, while diagnostic testing is pending. Issues related to treatment of influenza are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">
          "Seasonal influenza in nonpregnant adults: Treatment"
         </a>
         .)
        </p>
        <p>
         After treatment is completed, ongoing antiviral prophylaxis should be administered according to the protocol on the ward; the approach is discussed below. (See
         <a class="local">
          'Patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H771282065">
         <span class="h2">
          Approach to antiviral prophylaxis
         </span>
        </p>
        <p class="headingAnchor" id="H53664011">
         <span class="h3">
          Patients
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical approach
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Threshold for initiating prophylaxis
         </strong>
         – The optimal threshold for initiation of antiviral prophylaxis is uncertain.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If two cases of influenza are identified within 72 hours on the same unit, we favor administration of antiviral prophylaxis to all other asymptomatic patients on the unit (in the absence of suspected or laboratory-confirmed influenza), regardless of vaccination status [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Influenza virus transmission to an additional unit should prompt consideration of facility-wide antiviral prophylaxis [
         <a href="#rid2">
          2
         </a>
         ]. Such decisions should be guided by local circumstances including ventilation quality and whether there is mixing of staff, residents, and/or care equipment between units.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antiviral selection and dosing
         </strong>
         − Antiviral agents for prophylaxis include oral
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         or inhaled
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         ; dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef50350" href="/z/d/graphic/50350.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         resistance is known or suspected,
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         is an acceptable alternative to
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         ; however, baloxavir has not been studied for prophylaxis in the setting of institutional outbreaks, and caution regarding widespread use of this baloxavir for prophylaxis is warranted given its vulnerability to emergence of resistance. In addition, baloxavir is not recommended for pregnant or postpartum patients given lack of safety and efficacy data [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Given risk for emergence of antiviral resistance among severely immunocompromised individuals (who can have prolonged and asymptomatic influenza virus replication) [
         <a href="#rid14">
          14
         </a>
         ], for such individuals administration of neuraminidase inhibitor treatment dosing rather than prophylaxis dosing (eg, twice daily rather than once daily) for five days is reasonable, followed by reduction to prophylaxis dosing for the remainder of the outbreak [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Duration of prophylaxis
         </strong>
         − Prophylaxis with
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         or
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         should be continued for at least 14 days and for at least 7 days after onset of symptoms in the last identified case [
         <a href="#rid1">
          1,2
         </a>
         ]. The optimal duration of
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         for prophylaxis is uncertain; a single dose was found to be effective in the setting of household exposure [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Active surveillance
         </strong>
         − Individuals receiving antiviral prophylaxis who develop any signs or symptoms of influenza should be switched to receive antiviral treatment dosing. (See
         <a class="local">
          'Active surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supporting evidence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In long-term care settings, studies evaluating antiviral prophylaxis include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A trial including more than 480 long-term care facility residents (with 90 percent vaccination rate) in an influenza outbreak settings randomly assigned to receive
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         or
         <a class="drug drug_general" data-topicid="9866" href="/z/d/drug information/9866.html" rel="external">
          rimantadine
         </a>
         ; symptomatic, laboratory-confirmed influenza occurred less frequently among those who received zanamivir (3 versus 8 percent) [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A cluster-randomized trial including 16 long-term care facilities with influenza outbreaks in which patients received
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         for treatment or treatment followed by prophylaxis for 10 days; the influenza attack rate was lower among those who received treatment and prophylaxis than among those who received treatment alone (23 versus 36 percent) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         No randomized trials have been conducted to assess the optimal duration of prophylaxis; the approach described above is guided by the incubation period as well as observational data [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In hospitals, data on the effectiveness of antiviral prophylaxis for controlling influenza outbreaks are limited; use of prophylaxis has been described in conjunction with other control interventions [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3566973422">
         <span class="h3">
          Health care workers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Influenza vaccine should be administered to all health care personnel each season; the vaccine is more likely to be immunogenic among health care personnel than among patients. (See
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults"
         </a>
         .)
        </p>
        <p>
         For unvaccinated personnel, antiviral prophylaxis is reasonable for those who are household contacts of a person at high risk of influenza complications (see
         <a class="local">
          'Postexposure antiviral prophylaxis'
         </a>
         above), for the duration of the outbreak. Such individuals should be vaccinated promptly; the duration of antiviral prophylaxis for vaccinated individuals is 14 days following vaccination [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         In settings with risk for limited clinical staffing, antiviral prophylaxis for all personnel (regardless of vaccination status) is reasonable, for the duration of the outbreak.
        </p>
        <p>
         Antiviral agents for prophylaxis include oral
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         or inhaled
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         ; dosing for antiviral prophylaxis is summarized in the table  (
         <a class="graphic graphic_table graphicRef50350" href="/z/d/graphic/50350.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          Baloxavir
         </a>
         is an acceptable alternative to
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         when
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         resistance is known or suspected; however, baloxavir has not been studied for prophylaxis in the setting of institutional outbreaks, and caution regarding widespread use of baloxavir for prophylaxis is warranted given its vulnerability to emergence of resistance.
        </p>
        <p>
         There are no data evaluating the effectiveness of antiviral prophylaxis for health care workers to control influenza outbreaks.
        </p>
        <p class="headingAnchor" id="H1005258701">
         <span class="h2">
          Other interventions for prevention and control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other components of outbreak control include initiation of precautions, offering influenza vaccination to unvaccinated staff and residents, restricting contact between residents and ill staff or visitors, and restricting staff movement between sites [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6999.html" rel="external">
          "Infection control measures for prevention of seasonal influenza"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3678437961">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111532.html" rel="external">
          "Society guideline links: Treatment and prevention of seasonal influenza with antivirals"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/3992.html" rel="external">
          "Patient education: Influenza prevention (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         − Vaccination is the most important tool for influenza prevention. Antiviral drugs may be useful adjunctive tools in certain circumstances but should not be used as a substitute for vaccination. There is no role for routine use of antiviral drugs for prevention of influenza. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of pre-exposure prophylaxis
         </strong>
         − In community settings, we suggest pre-exposure prophylaxis in the following circumstances (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals at high risk of influenza complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ) for whom influenza vaccination is contraindicated, unavailable, or expected to have low effectiveness (due to immunosuppression or mismatch between vaccine antigens and circulating virus strains)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals at high risk of influenza complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ) for whom influenza vaccination is expected to be effective but has not yet been administered
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals for whom influenza vaccination is contraindicated, unavailable, or expected to have low effectiveness, who are in close contact with individuals in the above categories who are unable to take chemoprophylaxis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of postexposure prophylaxis
         </strong>
         − In community settings, we suggest postexposure prophylaxis (within 48 hours of exposure) in the following circumstances (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals at high risk of influenza complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ) for whom influenza vaccination is contraindicated, unavailable, or expected to have low effectiveness (eg, due to immunosuppression or mismatch between vaccine antigens and circulating virus strains)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Unvaccinated individuals who are household contacts of a person at high risk of influenza complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Institutional outbreak control
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Active surveillance (daily assessment for signs and symptoms of influenza) should be implemented in the following circumstances:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a long-term care facility − Identification of one laboratory-confirmed case of influenza
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In a hospital − Identification of one health care-associated laboratory-confirmed case of influenza
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Influenza testing should be pursued for patients with new respiratory symptoms, abnormal temperature (elevation or reduction), or behavioral changes, followed by initiation of empiric antiviral treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For units with two influenza cases identified within 72 hours, we suggest administration of antiviral prophylaxis to all other asymptomatic patients on the unit (in the absence of suspected or laboratory-confirmed influenza) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiviral selection
         </strong>
         − For antiviral prophylaxis, we suggest
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         or
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          Baloxavir
         </a>
         is an alternative agent for postexposure prophylaxis for nonpregnant patients. Dosing and duration of antiviral agents are summarized in the table  (
         <a class="graphic graphic_table graphicRef50350" href="/z/d/graphic/50350.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Centers for Disease Control and Prevention. Influenza antiviral medications: Summary for clinicians. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Accessed on October 22, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis 2019; 68:e1.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. https://www.cdc.gov/flu/professionals/antivirals/avrec_ob.htm (Accessed on January 04, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cowling BJ, Zhou Y, Ip DK, et al. Face masks to prevent transmission of influenza virus: a systematic review. Epidemiol Infect 2010; 138:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kashiwagi S, Watanabe A, Ikematsu H, et al. Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza. Clin Infect Dis 2016; 63:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, et al. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother 2010; 54:1834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           L'Huillier AG, Abed Y, Petty TJ, et al. E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient. J Infect Dis 2015; 212:1726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamura D, DeBiasi RL, Okomo-Adhiambo M, et al. Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir. J Infect Dis 2015; 212:1209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341:1336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaForce C, Man CY, Henderson FW, et al. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2007; 29:1579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow EJ, Beigi RH, Riley LE, Uyeki TM. Clinical Effectiveness and Safety of Antivirals for Influenza in Pregnancy. Open Forum Infect Dis 2021; 8:ofab138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson RJ, Cooper KL, Tappenden P, et al. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect 2011; 62:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. N Engl J Med 2020; 383:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Memoli MJ, Athota R, Reed S, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis 2014; 58:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gravenstein S, Drinka P, Osterweil D, et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. J Am Med Dir Assoc 2005; 6:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Booy R, Lindley RI, Dwyer DE, et al. Treating and preventing influenza in aged care facilities: a cluster randomised controlled trial. PLoS One 2012; 7:e46509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang YM, Li WC, Huang CT, et al. Use of oseltamivir during an outbreak of influenza A in a long-term care facility in Taiwan. J Hosp Infect 2008; 68:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorišek Miksić N, Uršič T, Simonović Z, et al. Oseltamivir prophylaxis in controlling influenza outbreak in nursing homes: a comparison between three different approaches. Infection 2015; 43:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higa F, Tateyama M, Tomishima M, et al. Role of neuraminidase inhibitor chemoprophylaxis in controlling nosocomial influenza: an observational study. Influenza Other Respir Viruses 2012; 6:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7017 Version 54.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Centers for Disease Control and Prevention. Influenza antiviral medications: Summary for clinicians. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Accessed on October 22, 2020).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30566567" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30566567" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20092668" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Face masks to prevent transmission of influenza virus: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27118785" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20194700" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25985905" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25943200" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10536125" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17919541" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34189160" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clinical Effectiveness and Safety of Antivirals for Influenza in Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20950645" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32640124" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24186906" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16286056" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23082123" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Treating and preventing influenza in aged care facilities: a cluster randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17945389" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Use of oseltamivir during an outbreak of influenza A in a long-term care facility in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25403263" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Oseltamivir prophylaxis in controlling influenza outbreak in nursing homes: a comparison between three different approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22118572" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Role of neuraminidase inhibitor chemoprophylaxis in controlling nosocomial influenza: an observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21248682" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP).
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
